All those who’re ‘Allergic,’ check your pen-injector of epinephrine
Some models of the product Jexthave a manufacturing defect. Better bring the pharmacy for an exchange. These pens containing adrenaline are necessary in case of severe allergic reaction.
For two years, insulin pens adrenaline that allergy sufferers should use any emergency in case of severe reaction (anaphylaxis) are regularly out of stock. A defect in the mechanism requires manufacturers to recall certain lots.
50,000 PENS ADRENALINE RECALLED
So last December, 50,000 Jext insulin pens may be defective were recalled by the KLA laboratory. It is estimated that only 0.04% are not operational. As a precaution, the entire lot must be reported. Patients in principle informed by their allergist are invited to share their pen Jext pharmacy model against an EpiPen. The exchange may take ten days. In the meantime, better keep it with his former pen, if necessary, waiting to recover again.
However, according to the National Security Agency of the drug (MSNA) only a third of these pens were made Jext dated February 7. The potential for accidents seriously concerned Couratier Pascale, president of the AFPRAL (French Association for the Prevention of allergies). “These pens are supposed to save the lives of people with allergies. These are really emergency medicine,” she recalls.
The arrival on the market pens Jext there just a year ago, yet represented a “relief” to the president of the AFPRAL. At the time, the Anapen model (laboratory Bioprojet), which was the only model available, was found also out of stock for a quality defect. Each time, laboratories rely complex manufacturing processes.
NOT ENOUGH PENS FOR ALL PATIENTS
But Pascale Couratier, the situation becomes intolerable. “There are not enough pens for all patients. We are all the time to lean. Labs are they trying to achieve economies of scale? We do not know,” she laments.
This is all the more incomprehensible that the High Authority of Health recommends allergic to wear them two pens, to avert a possible malfunction.
A glimmer of hope: The EpiPen, which until now was available in troubleshooting, should be officially sold in 2014 current. The AFPRAL estimated that each year 200,000 pens self-injectable epinephrine are sold in France.
